Idorsia Ltd (IDIA) Earnings Call Transcripts
Idorsia Ltd's Latest Earnings Call - March 31, 2026
In the first quarter of fiscal year 2026, Idorsia Ltd reported significant advancements in its daridorexant program for pediatric insomnia, highlighted by a successful Phase II study involving 165 children. The study demonstrated a statistically significant improvement in total sleep time, particularly in children with neurodevelopmental disorders, positioning daridorexant as a potential first-in-class treatment for pediatric insomnia. Management emphasized the drug's unique pharmacokinetic profile and its promising safety and tolerability, which could strengthen its market position among prescribers treating both adults and children. No specific revenue or earnings figures were disclosed during the call, and guidance was not explicitly provided, leaving future financial impacts uncertain.
Reported metrics
| Metric | Value |
|---|---|
| Study Participants | 165 (null) |
| Total Sleep Time Improvement | Statistically significant (positive) |
| Safety Events Reported | Minimal (positive) |
| Potential Pediatric Market Size | Millions (positive) |
| Regulatory Discussions Planned | Yes (neutral) |
Guidance from management
Management did not provide specific financial guidance or projections for future revenue related to daridorexant but emphasized ongoing discussions with health authorities regarding the drug's development in pediatric populations.
What management said
To answer your question on the repercussion for adults, I think, we have really a duplication or a replication of the amazing efficacy and safety profile in children. We knew daridorexant efficacy and safety at the same doses without dose adaptation in elderly, we are learning progressively that in patients with nocturia, as published, the efficacy on sleep also was replicated. Every time we are reproducing that this...
Thank you, Nadia. If there are no further questions, we will conclude today's call. Thank you all for joining us today to look at these exciting results. Nadia, please close the lines.
What analysts pressed on
Analysts expressed interest in the scope of clinical development for daridorexant in neurodevelopmental disorders and the potential market opportunity. There were concerns about the specifics of future studies and timelines, as well as the financial implications of these developments.
Main topics on the call
- Pediatric Insomnia Study Results — The Phase II study of daridorexant in children showed a 'highly statistically significant dose response' with improvements in total sleep time, especially in those with neurodevelopmental disorders. Management noted, 'th...
- Safety and Tolerability Profile — Management highlighted the 'clean safety and tolerability profile' of daridorexant in children, with no significant adverse events reported. This reinforces confidence in the drug's use among prescribers treating both ad...
- Market Opportunity — Jean-Paul Clozel mentioned a substantial unmet medical need in pediatric insomnia, stating, 'millions of children experienced chronic insomnia that profoundly affects daytime functioning.' This positions daridorexant fav...
- Future Development Plans — Management indicated plans to discuss further studies with health authorities to explore daridorexant's potential in neurodevelopmental disorders. They stated, 'we need to fully evaluate the surprising results' seen in t...
Read the full Idorsia Ltd transcript (March 31, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Idorsia Ltd
Idorsia Ltd (IDIA) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on SWX and is based in CH. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 32 calls on record spanning February 6, 2020 to July 30, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 32 Idorsia Ltd earnings call transcripts on record, spanning February 6, 2020 to July 30, 2026. Based on this history, Idorsia Ltd reports quarterly. The most recent call on file is dated July 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- IDIA
- Exchange
- SWX
- Country
- CH
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 32
- First call
- February 6, 2020
- Most recent
- July 30, 2026
- Reporting cadence
- quarterly